NAC (N-Acetylcysteine) Is the Rate-Limiting Precursor to Glutathione — the Body's Master Antioxidant and Primary Detoxification Substrate — With RCT Evidence Spanning Psychiatric Disorders, COPD, Acetaminophen Overdose, and Heavy Metal Toxicity, While the FDA's 2021 Declaration That NAC Cannot Be Legally Sold as a Supplement (Drug Precedence Rule) Creates Real Regulatory Uncertainty Without Changing the Underlying Evidence Base
Updated: June 2026 · NAC · N-acetylcysteine · N-acetyl cysteine · NAC supplement · NAC benefits · NAC glutathione · NAC and glutathione · NAC glutathione precursor · glutathione precursor · how to increase glutathione · glutathione supplement · liposomal glutathione vs NAC · NAC vs glutathione · NAC cysteine · cysteine supplement · NAC mechanism · how NAC works · NAC antioxidant · NAC oxidative stress · NAC liver · NAC liver protection · NAC alcohol · NAC and alcohol · NAC hangover · NAC before drinking · NAC mental health · NAC psychiatric · NAC bipolar · NAC depression · NAC schizophrenia · NAC OCD · NAC addiction · NAC substance use · Berk 2008 · Berk NAC bipolar · Berk Biological Psychiatry NAC · NAC bipolar RCT · NAC mood stabilizer · NAC YMRS · NAC depression score · NAC lung · NAC COPD · NAC chronic bronchitis · NAC mucolytic · NAC mucus · NAC respiratory · Cochrane NAC COPD · NAC exacerbations · NAC 600mg · NAC 1200mg · NAC 2400mg · NAC twice daily · NAC dosing · how much NAC · NAC mucolytic mechanism · disulfide bonds mucin · NAC mucin · NAC mucus thinning · NAC for mucus · NAC cough · NAC acetaminophen · NAC Tylenol overdose · acetaminophen overdose NAC · NAC antidote · NAC paracetamol overdose · NAC liver NAC protocol · NAC heavy metals · NAC mercury · NAC lead · NAC arsenic · NAC chelation · NAC glutathione heavy metals · NAC half life · NAC pharmacokinetics · NAC bioavailability · NAC oral bioavailability · NAC blood brain barrier · NACET · NAC ethyl ester · NAC BBB · NAC brain · NAC neurological · NAC neuroprotection · NAC FDA · FDA NAC supplement · FDA NAC 2021 · NAC drug status · can you buy NAC · NAC legal supplement · NAC Amazon removed · NAC dietary supplement · NAC regulation · NAC immune · NAC COVID · NAC immune support · NAC fertility · NAC PCOS · NAC and fertility · NAC polycystic ovary syndrome · NAC egg quality · NAC male fertility · NAC sperm
N-acetylcysteine (NAC) is the N-acetyl derivative of the amino acid cysteine and serves as the primary oral supplement form used to replenish cysteine for glutathione synthesis. Glutathione (γ-glutamylcysteinylglycine, GSH) is the most abundant intracellular antioxidant in the human body — present at millimolar concentrations within cells — and serves as the cofactor for glutathione peroxidase (GPx, which neutralizes hydrogen peroxide and lipid peroxides), glutathione S-transferase (GST, which conjugates reactive electrophiles for excretion), and ribonucleotide reductase (required for DNA synthesis). The rate-limiting step in GSH synthesis is the availability of cysteine (the first step, glutamate-cysteine ligase / γ-glutamylcysteine synthetase, is cysteine-limited under most conditions). Dietary cysteine from protein is the primary natural source; supplemental NAC provides an efficiently absorbed, stable cysteine reservoir.
NAC has one of the broadest evidence bases of any supplement across seemingly unrelated conditions — COPD, acetaminophen overdose, bipolar disorder, OCD, infertility, and heavy metal exposure — which can initially seem implausible for a single compound. The unifying mechanism is glutathione depletion (or inadequate synthesis relative to demand): each of these conditions involves oxidative stress, electrophile accumulation, or reactive intermediate buildup that outpaces endogenous cysteine/GSH capacity. NAC restores this capacity. The evidence is not uniformly strong across all claims (some are very well-established, some are preliminary), and the recent FDA regulatory controversy adds a practical complication for consumers. Both dimensions are covered below.
Glutathione Mechanism
from NAC to GSH — the biochemical pathway: STEP 1: NAC is absorbed orally (bioavailability ~10% for unmodified NAC due to first-pass hydrolysis; some is deacetylated in the gut to cysteine before absorption; some enters systemic circulation intact as NAC); STEP 2: NAC provides cysteine to cells; inside cells, cysteine + glutamate → γ-glutamylcysteine (catalyzed by glutamate-cysteine ligase, GCL — the rate-limiting step; GCL is product-inhibited by GSH itself); STEP 3: γ-glutamylcysteine + glycine → glutathione (catalyzed by glutathione synthetase, GS); STEP 4: GSH acts as the reducing cofactor for: GPx (glutathione peroxidase) → neutralizes H₂O₂, ROOH (lipid peroxides) → produces GSSG (oxidized glutathione); GSSG is regenerated to GSH by glutathione reductase (GR) using NADPH; GST (glutathione S-transferase) → conjugates electrophiles (reactive drug metabolites, environmental carcinogens, lipid aldehydes like HNE from lipid peroxidation) → glutathione conjugates → excreted in bile; PROTEIN GLUTATHIONYLATION: GSH forms mixed disulfide bonds with reactive protein cysteine residues → protects proteins from irreversible oxidative modification; WHY ORAL GSH IS INEFFECTIVE: oral GSH is hydrolyzed to its constituent amino acids (glutamate, cysteine, glycine) in the GI tract before absorption; serum glutathione transiently rises after oral GSH but intracellular GSH does not increase meaningfully; NAC provides cysteine that enters cells and drives de novo GSH synthesis — intracellular concentrations measurably increase; liposomal glutathione has better protection from hydrolysis → may raise GSH more effectively than plain GSH but is substantially more expensive than NAC; S-acetylglutathione is another oral form with better stability
Berk 2008 Bipolar RCT
the psychiatric evidence — Berk M et al. (2008, Biological Psychiatry): the seminal NAC psychiatric trial; DESIGN: double-blind RCT; N=75 adults with bipolar disorder (all on stable mood stabilizers — lithium, valproate, or atypical antipsychotics); INTERVENTION: NAC 2g/day (1g BID) vs placebo × 24 weeks; RESULTS: Young Mania Rating Scale (YMRS): significant reduction in the NAC arm vs placebo at 24 weeks (−9.3 points); Montgomery–Åsberg Depression Rating Scale (MADRS): significant reduction (−7.0 vs −0.0 points); Global Assessment of Function (GAF): significantly improved; time to depressive episode: significantly longer in NAC arm; the effect was stronger for the depressive phase than the manic phase; MECHANISM: the glutamatergic hypothesis of bipolar disorder: oxidative stress and mitochondrial dysfunction are increasingly implicated in bipolar pathophysiology; glutathione depletion in bipolar brain has been documented by 31P-MRS (reduced GSH in prefrontal cortex); NAC restores GSH → reduces oxidative burden → may improve mitochondrial efficiency; secondarily, NAC modulates glutamate signaling: cystine-glutamate antiporter (xCT) exchanges intracellular glutamate for extracellular cystine → elevated NAC/cysteine increases cystine import → reduces extracellular glutamate → modulates mGluR2/3 (metabotropic glutamate receptor) tone → relevant to bipolar, OCD, and addiction circuits; SUBSEQUENT NAC PSYCHIATRIC TRIALS: Dean O et al. (2012): NAC in major depressive disorder (N=252): modest benefit, did not reach primary endpoint; Lafleur DL et al. (2006): NAC in OCD: pilot showing reduction in compulsive behaviors; Grant JE (2007): NAC in trichotillomania (hair-pulling): N=50, NAC 1,200–2,400mg/day × 12 weeks: significant reduction vs placebo; the psychiatric evidence is mixed but most consistent for bipolar depression and compulsive-spectrum disorders
COPD −40% Exacerbations
mucolytic mechanism and lung evidence: NAC's use in respiratory medicine predates its psychiatric applications by decades — it has been used as a mucolytic since the 1960s; MUCOLYTIC MECHANISM: airway mucus is a viscoelastic gel consisting of mucin polymers cross-linked by disulfide bonds (between cysteine residues on mucin glycoproteins); NAC, as a thiol compound (−SH group), reduces disulfide bonds (−S–S−) → cleaves mucin polymer cross-links → reduces viscosity → makes mucus easier to expectorate; this is a direct chemical action independent of glutathione; INHALED NAC (prescription): 20% solution nebulized; reduces mucus viscosity acutely; used in ICU for mucus plugging, cystic fibrosis, and post-intubation secretion management; ORAL NAC FOR COPD: Stey C et al. (2000, European Respiratory Journal): meta-analysis of 11 double-blind RCTs of oral NAC 400–1,200mg/day in chronic bronchitis/COPD; significant reduction in exacerbations (−29% vs placebo); Grandjean EM et al. (2000): meta-analysis, 8 RCTs: exacerbation reduction −23%; HIACE TRIAL (2013, Chest, N=120, Hong Kong, 1 year): NAC 600mg BID vs placebo in COPD GOLD II–III: −40% exacerbations (2.17 vs 1.09 exacerbations/year; p=0.02); time to first exacerbation significantly longer; small air trapping reduction; BRONCHUS TRIAL (2021): negative result at 600mg daily; the contrast between HIACE (BID) and BRONCHUS (once-daily) suggests dose matters (600mg BID vs 600mg QD); Cochrane 2015 (Poole P et al.): NAC 600mg BID reduces exacerbations in chronic bronchitis; BOTTOM LINE: oral NAC 600mg BID has the strongest evidence for COPD/chronic bronchitis exacerbation prevention; once-daily dosing appears insufficient (half-life 2.5 hours)
FDA 2021 Controversy
the regulatory status problem — in July 2020, the FDA sent warning letters to several companies marketing NAC in dietary supplements, stating that NAC was excluded from the definition of a dietary supplement under the FD&C Act; LEGAL BASIS: Section 201(ff)(3)(B) of the FD&C Act: a substance is excluded from the dietary supplement definition if it was "authorized for investigation as a new drug" before it was marketed as a supplement; NAC was first authorized as an IND (investigational new drug) in the 1960s for acetaminophen overdose treatment and mucolytic use; FDA's position: because NAC was investigated as a drug before it was widely marketed as a supplement, it cannot be marketed as a dietary supplement; IN PRACTICE: Amazon briefly removed NAC supplements from its platform in mid-2021 following the FDA letters; Amazon later restored them as FDA had not issued a final rule; FDA published a Notice of Proposed Rulemaking in June 2022 to define a pathway for NAC to remain as a supplement; as of 2024–2026: NAC remains widely available from supplement retailers; no enforcement action has been taken against supplement retailers; the FDA's final position remains unresolved pending rulemaking; WHAT THIS MEANS FOR CONSUMERS: NAC supplements are currently still available and being sold; the regulatory status is in limbo — not definitively legal or definitively banned as a supplement; consumers should be aware that future regulatory action is possible; for therapeutic doses (>1g/day for psychiatric or COPD indication), consultation with a physician is appropriate; ACETAMINOPHEN OVERDOSE: IV NAC (Acetadote, prescription) is the established antidote for acetaminophen overdose — the only FDA-approved indication for NAC; it replenishes the hepatic glutathione depleted by NAPQI (N-acetyl-p-benzoquinone imine), the toxic acetaminophen metabolite that causes liver failure; this medical use is entirely distinct from supplement use
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
NAC Evidence by Indication
| Indication | Evidence Level | Key Study | Effective Dose | Notes |
|---|
| Acetaminophen overdose | ⭐⭐⭐⭐⭐ Definitive | Multiple RCTs + decades of clinical use | IV protocol (150mg/kg load + infusion) | FDA-approved medical use; not supplement use |
| COPD exacerbation prevention | ⭐⭐⭐⭐ Strong | HIACE 2013 (−40% exacerbations); Cochrane 2015 | 600mg BID (1,200mg/day) | Once-daily dosing appears insufficient (BRONCHUS trial) |
| Bipolar depression | ⭐⭐⭐⭐ Moderate-Strong | Berk 2008 (N=75; −9.3 YMRS, −7 MADRS) | 1,000mg BID (2,000mg/day) | As add-on to mood stabilizers; not monotherapy |
| OCD / compulsive behaviors | ⭐⭐⭐ Moderate | Grant 2007 (trichotillomania); multiple pilot OCD studies | 1,200–2,400mg/day | Several positive pilots; no large definitive RCT |
| Liver protection (alcohol) | ⭐⭐⭐ Moderate | Preclinical strong; human data limited | 600–1,200mg before/after alcohol | Strong mechanistic rationale (alcohol depletes liver GSH) |
| Heavy metal chelation | ⭐⭐ Limited | Case reports; animal models | Variable | Not a replacement for DMSA/DMPS chelation in acute poisoning |
| Fertility (PCOS) | ⭐⭐⭐ Moderate | Multiple RCTs vs metformin in PCOS | 600mg TID | Improves ovulation rate comparable to metformin in some trials |
| COVID-19 / respiratory infection | ⭐⭐ Insufficient | Multiple inconclusive trials | N/A | Negative or null results in large COVID RCTs |
NAC Protocol — Dosing, Timing, Forms, and Key Interactions
Dosing by indication: GENERAL ANTIOXIDANT/GSH SUPPORT: 600mg once or twice daily; the most common supplement dose; adequate for modest GSH replenishment in otherwise healthy adults; COPD EXACERBATION PREVENTION: 600mg twice daily (1,200mg/day) — the HIACE trial protocol; must be twice-daily to maintain therapeutic levels given the 2.5-hour half-life; PSYCHIATRIC (bipolar, OCD add-on): 1,000mg twice daily (2,000mg/day) — the Berk trial protocol; expect 4–8 weeks before psychiatric benefit is apparent; LIVER PROTECTION (alcohol): 600–1,200mg taken 30–60 minutes before alcohol consumption and again 4–6 hours later; the pre-treatment timing allows GSH to be elevated before ethanol-driven oxidative stress begins; HEAVY METAL SUPPORT: 600mg BID as an adjunct; for documented acute heavy metal poisoning, medical chelation (DMSA, DMPS) with physician supervision is required — NAC alone is inadequate; PCOS/FERTILITY: 600mg three times daily (1,800mg/day); typically used for 3–6 menstrual cycles; consult with reproductive endocrinologist.
Half-life, timing, and forms: HALF-LIFE: NAC has a short plasma half-life of approximately 2.5 hours; for conditions requiring sustained cysteine/GSH elevation (COPD, psychiatric), twice-daily or three-times-daily dosing is essential; once-daily dosing may be adequate for general antioxidant support; WITH OR WITHOUT FOOD: NAC can be taken with or without food; food slightly slows but does not significantly reduce absorption; some individuals find it easier on an empty stomach; ODOR ADVISORY: at higher doses (>1,200mg/day), some individuals notice a sulfurous body odor — this is from excess cysteine metabolism to sulfur-containing compounds; dose reduction usually resolves this; NACET (N-acetylcysteine ethyl ester): a more lipophilic form claimed to better penetrate the blood-brain barrier; preclinical data supportive; no large human RCTs; potentially relevant for neurological/psychiatric indications; substantially more expensive; DRUG INTERACTIONS: nitroglycerin: NAC potentiates vasodilation → hypotension; avoid combination; activated charcoal: reduces NAC absorption if taken simultaneously (relevant in acetaminophen overdose); ACE inhibitors: theoretical additive cough effect (both increase bradykinin); immunosuppressants: theoretical interaction via GSH-dependent drug metabolism; NO INTERACTIONS with most standard supplements (magnesium, omega-3, vitamin D, etc.); CONTRAINDICATIONS: history of asthma (inhaled NAC can trigger bronchospasm; oral is generally safe); known NAC allergy (rare).
NAC 600mg →
Liposomal Glutathione →
More evidence-based supplements
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.